Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension (IPAH)
Status:
Terminated
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether the addition of inhaled iloprost is safe and
effective in patients with idiopathic pulmonary arterial hypertension who are already being
treated with the endothelin receptor antagonist bosentan.